COX-2: A target for colon cancer prevention

被引：256
|
作者：
Marnett, LJ
DuBois, RN
机构：
[1] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Biochem, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Chem, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Med, Nashville, TN 37232 USA
[4] Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res, Ctr Mol Toxicol,Dept Cell Biol, Nashville, TN 37232 USA
[5] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA
来源：
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY | 2002年 / 42卷
关键词：
cyclooxygenase; prostaglandins; NSAIDs; cancer; prevention;
D O I：
10.1146/annurev.pharmtox.42.082301.164620
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Disease prevention is one area that both public and governmental agencies strongly support owing to its potential for an improved lifestyle and a reduction in health care costs. In this review, we focus on the clinical development of one target for cancer prevention, the COX-2 enzyme. This provides an excellent example of how basic research in biochemistry and pharmacology can lead to translational studies and eventually to approval of a drug by the FDA for use as a chemopreventive agent in humans. It is hoped that, as the genome sequence: is understood more clearly, other targets will emerge that will provide even more effective drugs for future cancer prevention.
引用
收藏
页码：55 / +
页数：26
相关论文
共 50 条
  • [21] COX-2 and cancer: a new approach to an old problem
    Bakhle, YS
    BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (06) : 1137 - 1150
  • [22] Dysregulated post-transcriptional control of COX-2 gene expression in cancer
    Dixon, DA
    CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (06) : 635 - 646
  • [23] COX-2 Expression in Gastric Cancer
    Bekdemir, Handan
    Tekin, Salim B.
    Bilici, Mehmet
    Cayir, Kerim
    Gundogdu, Cemal
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2010, 20 (01): : 34 - 41
  • [24] COX-2 in Radiotherapy: A Potential Target for Radioprotection and Radiosensitization
    Cheki, Mohsen
    Yahyapour, Rasoul
    Farhood, Bagher
    Rezaeyan, Abolhassan
    Shabeeb, Dheyauldeen
    Amini, Peyman
    Rezapoor, Saeed
    Najafi, Masoud
    CURRENT MOLECULAR PHARMACOLOGY, 2018, 11 (03) : 173 - 183
  • [25] The role of COX-2 in oral cancer development, and chemoprevention/treatment of oral cancer by selective COX-2 inhibitors
    Wang, Z
    CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (14) : 1771 - 1777
  • [26] Gastrointestinal safety of selective COX-2 inhibitors
    Hawkey, CJ
    Skelly, MM
    CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (12) : 1077 - 1089
  • [27] COX-2 Signaling and Cancer: New Players in Old Arena
    Misra, Shashank
    Sharma, Kulbhushan
    CURRENT DRUG TARGETS, 2014, 15 (03) : 347 - 359
  • [28] Eicosanoids in inflammation and cancer: the role of COX-2
    Agarwal, Smita
    Reddy, Gorla Venkateswara
    Reddanna, Pallu
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2009, 5 (02) : 145 - 165
  • [29] Biology of Cox-2: An Application in Cancer Therapeutics
    Khan, Zakir
    Khan, Noor
    Tiwari, Ram P.
    Sah, Nand K.
    Prasad, G. B. K. S.
    Bisen, Prakash S.
    CURRENT DRUG TARGETS, 2011, 12 (07) : 1082 - 1093
  • [30] COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer
    Piazuelo, E
    Jimenez, P
    Lanas, A
    CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (27) : 2267 - 2280
12345